---
schema_version: "secwatch.filing_event.v1"
accession: "0000914475-23-000072"
form_type: "8-K"
ticker: "NBIX"
cik: "0000914475"
company_name: "NEUROCRINE BIOSCIENCES INC"
filed_at: "2023-10-31T23:59:59+00:00"
generated_at: "2026-06-09T05:24:35.967447+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Neurocrine Q3 INGREZZA sales $486M (+29% YoY); raises 2023 guidance to $1.82-1.84B

## Summary
- INGREZZA Q3 net sales $486M (+29% YoY); total product sales $492M.
- GAAP EPS $0.82; non-GAAP EPS $1.54. Cash & securities $1.55B.
- INGREZZA 2023 net sales guidance raised to $1.82-1.84B.
- FDA approved INGREZZA for Huntington's chorea; NDA accepted for oral granules (PDUFA Apr 30, 2024).
- Phase 3 crinecerfont met primary endpoints in adult and pediatric CAH; Analyst Day Dec 5.

## SEC filing metadata
- accession: 0000914475-23-000072
- form_type: 8-K
- ticker: NBIX
- cik: 0000914475
- company_name: NEUROCRINE BIOSCIENCES INC
- filed_at: 2023-10-31T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/914475/000091447523000072/0000914475-23-000072-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/914475/000091447523000072/nbix-20231031.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000914475-23-000072
- JSON: https://secwatch.observer/filing/0000914475-23-000072.json
- Plain text: https://secwatch.observer/filing/0000914475-23-000072.txt

## Key facts
- Earnings Releases
  NEUROCRINE BIOSCIENCES INC updated its the third quarter ended September 30, 2023 guidance (raised).
  - Period: the third quarter ended September 30, 2023
  - Guidance: raised
  - Result: reported results
  source text: On October 31, 2023, Neurocrine Biosciences, Inc. announced its financial results for the third quarter ended September 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/914475/000091447523000072/0000914475-23-000072-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.